M10/3/BUSMT/SP1/ENG/TZ0/XX




       22105013


BUSINESS AND MANAGEMENT
STANDARD LEVEL
PAPER 1

Tuesday 4 May 2010 (afternoon)

1 hour 15 minutes


INSTRUCTIONS to candidates

   Do not open this examination paper until instructed to do so.
   Read the case study carefully.
   Section A: answer two questions.
   Section B: answer the compulsory question.




2210-5013                                                                                            3 pages
                                                             © International Baccalaureate Organization 2010
                                                    –2–               M10/3/BUSMT/SP1/ENG/TZ0/XX

                                                  SECTION A

Answer two questions from this section.

1.    (a)   Define the following terms:

		          (i)    product life cycle (line 32)                                               [2 marks]

		          (ii)   brand loyalty (line 51).                                                   [2 marks]

      (b)   With reference to N-Pharma and its new drug Pharmatics, distinguish between
            “above the line and below the line promotion” (line 45).                          [4 marks]

      (c)   Apply The Boston Consulting Group (BCG) matrix to N-Pharma’s product
            portfolio.                                                                        [7 marks]


2.    (a)   “Since 1980, N-Pharma has been a public limited company with its shares
            traded on the Tokyo Stock Exchange” (lines 83–84). Outline two key aspects of
            this form of ownership.                                                           [4 marks]

      (b)   Prepare a SWOT analysis showing only the opportunities and threats
            for N-Pharma.                                                                     [4 marks]

      (c)   Analyse N-Pharma’s position using the information in the SWOT analysis
            (additional information, page 3) and your answer to part (b).                     [7 marks]


3.    (a)   Define the following terms:

		          (i)    profitability (line 64)                                                    [2 marks]

		          (ii)   liquidity (line 111).                                                      [2 marks]

      (b)   Using data from Appendix 2, calculate the liquidity ratios for the
            USA subsidiary of N-Pharma in the financial years 2008 and 2009.                  [4 marks]

      (c)   Analyse the liquidity ratios calculated in part (b) from the perspective of two
            stakeholders of N-Pharma.                                                         [7 marks]




2210-5013
                                                  –3–               M10/3/BUSMT/SP1/ENG/TZ0/XX

                                              SECTION B

Answer the compulsory question from this section.

4.    (a)   Define the following terms:

            (i)    delegation (line 59)                                                       [2 marks]

            (ii)   performance-related pay (PRP) (line 72).                                   [2 marks]

      (b)   N-Pharma is considering several strategic options for its future growth,
            including a takeover (Option 1(b)) and a merger (Option 3). Distinguish
            between a merger and a takeover.                                                  [4 marks]

      (c)   Laura Davies anticipates “that the Australian employees of N-Pharma will
            respond positively to non-financial rewards” (lines 80–81). Explain how
            non-financial rewards might affect job satisfaction and productivity.             [4 marks]

      (d)   To what extent would a change in Susan James’ leadership style improve
            productivity and morale at the Canadian subsidiary of N-Pharma?                   [8 marks]




Additional information

Strengths and weaknesses from a SWOT analysis for N-Pharma
Strengths
• N-Pharma is a well-established multinational company (MNC) with subsidiaries in several countries
   within the Pacific Rim.
• N-Pharma is a well known brand name, attracting customer loyalty.
• N-Pharma has a portfolio of drugs at different stages of their product life cycle (e.g. Pharmax,
   Pharmaflo, Pharmaslim, Pharmatics).
• N-Pharma has large financial reserves and its shares are regarded by investors as safe and relatively
   risk free.

Weaknesses
• N-Pharma has experienced problems in some of its subsidiaries (e.g. human resources (HR) problems
  in Canada and Australia, liquidity problems in the USA).
• N-Pharma has suffered a negative public image because of unethical practices.
• N-Pharma operates in a very competitive business environment (generic drugs from competitors are
  cheaper than N-Pharma branded products).




2210-5013
